A phase II study of BEZ235 in patients with everolimusresistant, advanced pancreatic neuroendocrine tumours

Nicola Fazio, Roberto Buzzoni, Eric Baudin, Lorenzo Antonuzzo, Richard A. Hubner, Harald Lahner, Wouter W. De Herder, Markus Raderer, Alexandre Teulé, Jaume Capdevila, Steven K. Libutti, Matthew H. Kulke, Manisha Shah, Debarshi Dey, Sabine Turri, Paola Aimone, Cristian Massacesi, Chris Verslype

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Background: This was a two-stage, phase II trial of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor BEZ235 in patients with everolimusresistant pancreatic neuroendocrine tumours (pNETs) (NCT01658436). Patients and Methods: In stage 1, 11 patients received 400 mg BEZ235 orally twice daily (bid). Due to tolerability concerns, a further 20 patients received BEZ235 300 mg bid. Stage 2 would be triggered by a 16-week progressionfree survival (PFS) rate of =60% in stage 1. Results: As of 30 June, 2014, 29/31 patients had discontinued treatment. Treatment-related grade 3/4 adverse events were reported in eight (72.7%) patients at 400 mg and eight (40.0%) patients at 300 mg, including hyperglycaemia, diarrhoea, nausea, and vomiting. The estimated 16-week PFS rate was 51.6% (90% confidence interval=35.7-67.3%). Conclusion: BEZ235 was poorly tolerated by patients with everolimus-resistant pNETs at 400 and 300 mg bid doses. Although evidence of disease stability was observed, the study did not proceed to stage 2. Pancreatic neuroendocrine tumours (pNETs) are rare malignancies, representing

Original languageEnglish (US)
Pages (from-to)713-720
Number of pages8
JournalAnticancer Research
Volume36
Issue number2
StatePublished - Feb 1 2016

Fingerprint

Neuroendocrine Tumors
Survival Rate
Phosphatidylinositol 3-Kinase
dactolisib
Sirolimus
Hyperglycemia
Nausea
Vomiting
Diarrhea
Confidence Intervals
Therapeutics

Keywords

  • BEZ235
  • Everolimus
  • MTOR
  • PI3K
  • PNETs

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Fazio, N., Buzzoni, R., Baudin, E., Antonuzzo, L., Hubner, R. A., Lahner, H., ... Verslype, C. (2016). A phase II study of BEZ235 in patients with everolimusresistant, advanced pancreatic neuroendocrine tumours. Anticancer Research, 36(2), 713-720.

A phase II study of BEZ235 in patients with everolimusresistant, advanced pancreatic neuroendocrine tumours. / Fazio, Nicola; Buzzoni, Roberto; Baudin, Eric; Antonuzzo, Lorenzo; Hubner, Richard A.; Lahner, Harald; De Herder, Wouter W.; Raderer, Markus; Teulé, Alexandre; Capdevila, Jaume; Libutti, Steven K.; Kulke, Matthew H.; Shah, Manisha; Dey, Debarshi; Turri, Sabine; Aimone, Paola; Massacesi, Cristian; Verslype, Chris.

In: Anticancer Research, Vol. 36, No. 2, 01.02.2016, p. 713-720.

Research output: Contribution to journalArticle

Fazio, N, Buzzoni, R, Baudin, E, Antonuzzo, L, Hubner, RA, Lahner, H, De Herder, WW, Raderer, M, Teulé, A, Capdevila, J, Libutti, SK, Kulke, MH, Shah, M, Dey, D, Turri, S, Aimone, P, Massacesi, C & Verslype, C 2016, 'A phase II study of BEZ235 in patients with everolimusresistant, advanced pancreatic neuroendocrine tumours', Anticancer Research, vol. 36, no. 2, pp. 713-720.
Fazio N, Buzzoni R, Baudin E, Antonuzzo L, Hubner RA, Lahner H et al. A phase II study of BEZ235 in patients with everolimusresistant, advanced pancreatic neuroendocrine tumours. Anticancer Research. 2016 Feb 1;36(2):713-720.
Fazio, Nicola ; Buzzoni, Roberto ; Baudin, Eric ; Antonuzzo, Lorenzo ; Hubner, Richard A. ; Lahner, Harald ; De Herder, Wouter W. ; Raderer, Markus ; Teulé, Alexandre ; Capdevila, Jaume ; Libutti, Steven K. ; Kulke, Matthew H. ; Shah, Manisha ; Dey, Debarshi ; Turri, Sabine ; Aimone, Paola ; Massacesi, Cristian ; Verslype, Chris. / A phase II study of BEZ235 in patients with everolimusresistant, advanced pancreatic neuroendocrine tumours. In: Anticancer Research. 2016 ; Vol. 36, No. 2. pp. 713-720.
@article{f359177b11d84d80bcbd589e8df0f633,
title = "A phase II study of BEZ235 in patients with everolimusresistant, advanced pancreatic neuroendocrine tumours",
abstract = "Background: This was a two-stage, phase II trial of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor BEZ235 in patients with everolimusresistant pancreatic neuroendocrine tumours (pNETs) (NCT01658436). Patients and Methods: In stage 1, 11 patients received 400 mg BEZ235 orally twice daily (bid). Due to tolerability concerns, a further 20 patients received BEZ235 300 mg bid. Stage 2 would be triggered by a 16-week progressionfree survival (PFS) rate of =60{\%} in stage 1. Results: As of 30 June, 2014, 29/31 patients had discontinued treatment. Treatment-related grade 3/4 adverse events were reported in eight (72.7{\%}) patients at 400 mg and eight (40.0{\%}) patients at 300 mg, including hyperglycaemia, diarrhoea, nausea, and vomiting. The estimated 16-week PFS rate was 51.6{\%} (90{\%} confidence interval=35.7-67.3{\%}). Conclusion: BEZ235 was poorly tolerated by patients with everolimus-resistant pNETs at 400 and 300 mg bid doses. Although evidence of disease stability was observed, the study did not proceed to stage 2. Pancreatic neuroendocrine tumours (pNETs) are rare malignancies, representing",
keywords = "BEZ235, Everolimus, MTOR, PI3K, PNETs",
author = "Nicola Fazio and Roberto Buzzoni and Eric Baudin and Lorenzo Antonuzzo and Hubner, {Richard A.} and Harald Lahner and {De Herder}, {Wouter W.} and Markus Raderer and Alexandre Teul{\'e} and Jaume Capdevila and Libutti, {Steven K.} and Kulke, {Matthew H.} and Manisha Shah and Debarshi Dey and Sabine Turri and Paola Aimone and Cristian Massacesi and Chris Verslype",
year = "2016",
month = "2",
day = "1",
language = "English (US)",
volume = "36",
pages = "713--720",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2",

}

TY - JOUR

T1 - A phase II study of BEZ235 in patients with everolimusresistant, advanced pancreatic neuroendocrine tumours

AU - Fazio, Nicola

AU - Buzzoni, Roberto

AU - Baudin, Eric

AU - Antonuzzo, Lorenzo

AU - Hubner, Richard A.

AU - Lahner, Harald

AU - De Herder, Wouter W.

AU - Raderer, Markus

AU - Teulé, Alexandre

AU - Capdevila, Jaume

AU - Libutti, Steven K.

AU - Kulke, Matthew H.

AU - Shah, Manisha

AU - Dey, Debarshi

AU - Turri, Sabine

AU - Aimone, Paola

AU - Massacesi, Cristian

AU - Verslype, Chris

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Background: This was a two-stage, phase II trial of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor BEZ235 in patients with everolimusresistant pancreatic neuroendocrine tumours (pNETs) (NCT01658436). Patients and Methods: In stage 1, 11 patients received 400 mg BEZ235 orally twice daily (bid). Due to tolerability concerns, a further 20 patients received BEZ235 300 mg bid. Stage 2 would be triggered by a 16-week progressionfree survival (PFS) rate of =60% in stage 1. Results: As of 30 June, 2014, 29/31 patients had discontinued treatment. Treatment-related grade 3/4 adverse events were reported in eight (72.7%) patients at 400 mg and eight (40.0%) patients at 300 mg, including hyperglycaemia, diarrhoea, nausea, and vomiting. The estimated 16-week PFS rate was 51.6% (90% confidence interval=35.7-67.3%). Conclusion: BEZ235 was poorly tolerated by patients with everolimus-resistant pNETs at 400 and 300 mg bid doses. Although evidence of disease stability was observed, the study did not proceed to stage 2. Pancreatic neuroendocrine tumours (pNETs) are rare malignancies, representing

AB - Background: This was a two-stage, phase II trial of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor BEZ235 in patients with everolimusresistant pancreatic neuroendocrine tumours (pNETs) (NCT01658436). Patients and Methods: In stage 1, 11 patients received 400 mg BEZ235 orally twice daily (bid). Due to tolerability concerns, a further 20 patients received BEZ235 300 mg bid. Stage 2 would be triggered by a 16-week progressionfree survival (PFS) rate of =60% in stage 1. Results: As of 30 June, 2014, 29/31 patients had discontinued treatment. Treatment-related grade 3/4 adverse events were reported in eight (72.7%) patients at 400 mg and eight (40.0%) patients at 300 mg, including hyperglycaemia, diarrhoea, nausea, and vomiting. The estimated 16-week PFS rate was 51.6% (90% confidence interval=35.7-67.3%). Conclusion: BEZ235 was poorly tolerated by patients with everolimus-resistant pNETs at 400 and 300 mg bid doses. Although evidence of disease stability was observed, the study did not proceed to stage 2. Pancreatic neuroendocrine tumours (pNETs) are rare malignancies, representing

KW - BEZ235

KW - Everolimus

KW - MTOR

KW - PI3K

KW - PNETs

UR - http://www.scopus.com/inward/record.url?scp=84961831124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961831124&partnerID=8YFLogxK

M3 - Article

VL - 36

SP - 713

EP - 720

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2

ER -